B+
Bull case
30%
Probability
Target price
$500.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
ELV
Elevance HealthBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$460.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$370.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-22
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.0
Score
AI commentary
The primary-source beat and guidance raise improve the prior neutral thesis, consistent with the deterministic positive change signal, but the initial market response was mixed: ELV closed October 21 at $434.13, down about 1.37% from the October 20 close of $440.18 (price history). Pre-print consensus was $4.66 EPS and $48.60 billion revenue (Zacks preview); verified post-print analyst target or estimate revisions are unavailable. Social, options and employee measures are not covered by the packet, so the sentiment figures other than headline buzz should not be treated as measured signals.
RankAlpha Sentiment Codex - 2026-10-22
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-11-15catalystPost-print reassessment of a qualified Q3 beatMedium impact
Q3 adjusted EPS of $6.99 exceeded the $4.66 pre-print Zacks consensus, and operating revenue of $50.4 billion exceeded its $48.60 billion estimate. The company attributes part of EPS to a $1.85-per-share net non-operating benefit, while its benefit expense ratio improved 70 basis points to 90.6%. Whether investors credit the operating improvement rather than the non-operating gain is the immediate question [#SEC-8K-2026-10-21].
2027-02-15eventDelivery against raised 2026 earnings and cash-flow floorsMedium impact
Elevance raised its FY2026 adjusted EPS floor from at least $27.00 after Q2 to at least $29.00 after Q3, and raised operating cash-flow guidance to at least $6.5 billion. Year-end delivery will test whether improved claims performance offsets membership declines and higher operating expenses; the date is an estimated monitoring window, not an announced earnings date [#SEC-8K-2026-07-15] [#SEC-8K-2026-10-21].
2027-12-31catalystValidate the 2027 adjusted EPS growth objectiveHigh impact
Management reiterated confidence in at least 12% adjusted EPS growth in 2027 from a 2026 baseline of at least $26.75 that excludes specified non-recurring items and targeted one-time investments. Durable medical-cost control and Carelon gains must translate into recurring earnings for that objective to support a higher valuation; the date is a monitoring horizon [#SEC-8K-2026-10-21].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-22 • Updated nightlySource: Internal modelMethodology